Gemigliptin tartrate is primarily used in the management of type 2 diabetes mellitus. It functions by enhancing the body's natural ability to regulate blood glucose levels. This compound helps increase insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia. It also suppresses glucagon levels, which in turn lowers hepatic glucose production. Due to its selective inhibition of the DPP-4 enzyme, it prolongs the activity of incretin hormones like GLP-1 and GIP, improving glycemic control. It is often prescribed as a monotherapy or in combination with other antidiabetic agents such as metformin. Its favorable pharmacokinetic profile allows for once-daily dosing, contributing to improved patient compliance.